---
from: markdown+emoji
execute: 
  cache: true
format: 
  letterbox-revealjs:
    css: [custom.css, hex.css, timeline.css]
    progress: false
    menu: false
    width: 1280
    height: 720
callout-appearance: simple
editor_options: 
  chunk_output_type: console
---

```{r setup, include=FALSE}
library(rmarkdown)
library(magrittr)
```

## {}

::: columns
::: {.column width="40%"}

:::
::: {.column width="60%"}

::: {.title data-id="title"}
PHUSE End-to-End OS Collaboration Guidance
:::

::: {.dateplace}
2023-11-06 @ PHUSE EU 2023
:::

##### James Black & Mike Stackhouse

::: {.callout-note icon=false}

Links to the guidance and slides

![](img/icon-webdoc.png){.icon} [phuse-org.github.io/E2E-OS-Guidance/](https://phuse-org.github.io/E2E-OS-Guidance/)

![](img/icon-presentation.png){.icon} [phuse-org.github.io/E2E-OS-Guidance/slides/eu23](https://phuse-org.github.io/E2E-OS-Guidance/slides/eu23/)

:::

:::
:::

![](img/website-app.png){.image-left}

## Why is guidance needed?

:::: {layout="[ 40, 60 ]"}

::: {#first-column}
![](img/pharmaverse-pkg.jpg)
:::

::: {#second-column}

- `pharmaverse` brings a new open source R-backbone to clinical reporting
- most packages are collaborations
- there is a shift towards more sharing of useful code

::: {.fragment}
::: {.callout-warning}

## New territory for stastisical programmers!
- Can we rely on OS code?
- What if these collaborations fall apart?
- Are we at risk?
- How can we influence development?
:::
:::

:::

::::

## Our aim

Provide guidance tackling the core questions raised by PHUSE members around:

::: {.incremental}
  1. Using open OS :gear:
  2. Releasing OS code :rocket:
  3. Collaborating and governing OS :handshake:
  4. Why OS'ing our code is important! :mega:
:::

::: {.fragment}
::: {.callout-note}
While *technically* legacy propriety code could be OS, and other languages are present like python, to align with the *pharmaverse* we decided to frame the guidance around R packages.
:::
:::

## PHUSE E2E OS Guidance Working Group

```{r}
dplyr::tribble(
  ~Name, ~Company,
  "James Black", "Roche",
  "Mike Stackhouse", "Atorus",
  "Anders Bilgrau, Tobias KrÃ¸gholt", "Novo",
  "Estella Dong,  Karl Brand", "Bayer",
  "Keaven Anderson", "Merck",
  "Phil Bowsher, Ryan Johnson", "Posit",
  "Samir Parmar", "Pfizer"
  ) %>%
  dplyr::mutate(
    Company = glue::glue("img/logo_{tolower(Company)}.png")
  ) %>%
  gt::gt() %>%
  gtExtras::gt_img_rows(columns = Company, height = 26)



```

## The guidance is available now!

::: {.callout-note}
## Guidance document
[phuse-org.github.io/E2E-OS-Guidance/](https://phuse-org.github.io/E2E-OS-Guidance/)
:::

::: {.fragment}
::: {.callout-caution}
This is a living document, please be vocal and contribute! 

If you see something in this presentation you want to comment on, improve or challenge...

- Talk to a working group member 
- Make an issue
- Make a PR on the document repository
:::
:::


## Getting deeper into the guidance :diving_mask:

## {.fragment-remove}

::: {.fragment .fade-out fragment-index=1}
### A brief overview
:::


::: columns
::: {.column width="60%"}

::: {.container .fragment .fade-up fragment-index=1}
::: {.timeline .timeline-left style="height: 720px;"}



::: {.timeline-block}

::: {.timeline-content}
An intro as to why OS and collaborate

::: {.timeline-details .fragment .fade-out fragment-index=2}

[We are already deeply leveraging OS, and by pooling resources on pre/post we can focus more on generating value]{style="padding-top:20px;display:block;"}

[Every external contribution offers the chance to get back more than we invested]{style="padding-top:20px;display:block;"}

[Is it ethically ok to **not** have key scientific logic done in an open source license free language?]{style="padding-top:20px;display:block;"}

:::
::: {.timeline-date}
The why
:::
:::
:::



::: {.timeline-block .fragment .fade-up fragment-index=2}

::: {.timeline-content}
Project health, risks and licences

::: {.timeline-details .fragment .fade-out fragment-index=3}
[Examples are given on how to assess how engaged and active the community are, and what resources are available to find packages - like the [`pharmaverse`](pharmaverse.org) and [`openstatsware`](https://rconsortium.github.io/asa-biop-swe-wg/)]{style="padding-top:20px;display:block;"}

[A discussion of the risks, and tools to assess risk and the impact of different licences]{style="padding-top:20px;display:block;"}
:::
::: {.timeline-date}
Using OS
:::
:::
:::



::: {.timeline-block .fragment .fade-up fragment-index=3}
::: {.timeline-content}
Releasing, collaborating and governing OS

::: {.timeline-details .fragment .fade-out fragment-index=4}
[Understanding pre-competitive, competitive, and *post-competitive* IP.]{style="padding-top:20px;display:block;"}

[Guidance on robust and safe release processes.]{style="padding-top:20px;display:block;"}

[Examples of different governance models.]{style="padding-top:20px;display:block;"}
:::
::: {.timeline-date}
Releasing
:::
:::
:::

:::
:::


:::
:::

## Demo navigating the guidance




[phuse-org.github.io/E2E-OS-Guidance/ :link:](https://phuse-org.github.io/E2E-OS-Guidance/)